VEGFA and Sepsis: While anti-VEGF neutralising antibody bevacizumab showed variable results in mouse sepsis (173, 174), a clinical trial was set up to test its effectiveness in sepsis patients, in particular in preventing development of sepsis-associated acute respiratory distress syndrome.